English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#sclerodermaforum search results

ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 22

📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch

ScleroForum's tweet image. 📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch
0
0
0
0
52
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 6

⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E

ScleroForum's tweet image. ⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E
0
0
1
0
34
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 2

📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z

ScleroForum's tweet image. 📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z
0
0
0
0
23
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 29

👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za

ScleroForum's tweet image. 👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za
0
0
1
0
60
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 30

The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y

ScleroForum's tweet image. The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y
0
0
1
0
57
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Sep 24

👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR

ScleroForum's tweet image. 👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR
0
0
0
0
28
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 4

Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U

ScleroForum's tweet image. Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U
0
0
1
0
48
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 8

The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8

ScleroForum's tweet image. The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8
0
0
0
0
40
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 5

In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm

ScleroForum's tweet image. In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm
0
0
0
0
37
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 25

Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum

ScleroForum's tweet image. Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum
0
0
0
0
33
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 28

In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum

ScleroForum's tweet image. In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum
0
0
0
0
25
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 1

This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…

ScleroForum's tweet image. This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…
0
0
0
0
31
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY

ScleroForum's tweet image. Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY
0
0
1
0
31
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 14

🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G

ScleroForum's tweet image. 🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G
0
0
0
0
32
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 31

After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG

ScleroForum's tweet image. After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG
0
0
0
0
64
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug

ScleroForum's tweet image. 🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug
0
0
1
0
68
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 22

📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch

ScleroForum's tweet image. 📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch
0
0
0
0
52
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 14

🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G

ScleroForum's tweet image. 🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G
0
0
0
0
32
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 6

⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E

ScleroForum's tweet image. ⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E
0
0
1
0
34
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 2

📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z

ScleroForum's tweet image. 📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z
0
0
0
0
23
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Sep 24

👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR

ScleroForum's tweet image. 👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR
0
0
0
0
28
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 8

The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8

ScleroForum's tweet image. The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8
0
0
0
0
40
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 5

In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm

ScleroForum's tweet image. In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm
0
0
0
0
37
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 4

Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U

ScleroForum's tweet image. Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U
0
0
1
0
48
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 1

This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…

ScleroForum's tweet image. This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…
0
0
0
0
31
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 31

After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG

ScleroForum's tweet image. After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG
0
0
0
0
64
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 31

📰Our latest #Scleroderma literature highlights, featuring research by Denton, et al. are now live on the #SclerodermaForum. Access these comprehensive slide decks for the latest insights in Scleroderma treatment: ow.ly/VlA750WnvWE

ScleroForum's tweet image. 📰Our latest #Scleroderma literature highlights, featuring research by Denton, et al. are now live on the #SclerodermaForum. Access these comprehensive slide decks for the latest insights in Scleroderma treatment: ow.ly/VlA750WnvWE
0
0
0
0
30
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 30

The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y

ScleroForum's tweet image. The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y
0
0
1
0
57
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 29

👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za

ScleroForum's tweet image. 👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za
0
0
1
0
60
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 29

🔔Stay informed with our latest #Scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/ufVP50WnvZk

ScleroForum's tweet image. 🔔Stay informed with our latest #Scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/ufVP50WnvZk
0
0
0
0
37
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 28

In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum

ScleroForum's tweet image. In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum
0
0
0
0
25
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 25

Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum

ScleroForum's tweet image. Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum
0
0
0
0
33
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY

ScleroForum's tweet image. Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY
0
0
1
0
31
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug

ScleroForum's tweet image. 🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug
0
0
1
0
68
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 23

🔎Discover the newest findings in #Scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/tPqL50Wnw2Z

ScleroForum's tweet image. 🔎Discover the newest findings in #Scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/tPqL50Wnw2Z
0
0
1
0
32
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 18

💡Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/q0fn50Wnuhz

ScleroForum's tweet image. 💡Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/q0fn50Wnuhz
0
0
0
0
37
No results for "#sclerodermaforum"
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 22

📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch

ScleroForum's tweet image. 📑Our latest #scleroderma literature highlights, featuring research by Chung et al., are now live on the #SclerodermaForum. 👉Access these comprehensive slide decks for the latest insights in #scleroderma treatment: ow.ly/ISHJ50WYOch
0
0
0
0
52
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Sep 24

👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR

ScleroForum's tweet image. 👀Looking for the latest insights in #scleroderma? Our new slide deck and literature highlights are live on the #SclerodermaForum. 🔗Access these valuable resources today: ow.ly/wW5E50WYNWR
0
0
0
0
28
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 2

📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z

ScleroForum's tweet image. 📣 Stay informed with our latest #scleroderma literature highlights and detailed slide decks. Now available for free on the #SclerodermaForum: ow.ly/LWs150WYO4Z
0
0
0
0
23
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 6

⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E

ScleroForum's tweet image. ⭐ Enhance your understanding of #scleroderma with our newly uploaded slide deck and literature highlights. Visit the #SclerodermaForum today to access these free resources: ow.ly/KfY150WYO5E
0
0
1
0
34
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Oct 14

🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G

ScleroForum's tweet image. 🔎 Discover the newest findings in #scleroderma in our latest literature highlights. Enhance your clinical knowledge with free access on the #SclerodermaForum: ow.ly/1URA50WYO7G
0
0
0
0
32
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 29

👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za

ScleroForum's tweet image. 👉 #SclerodermaForum is featured in The Scleroderma Research Foundation (#SRF) July eNewsletter. Read the newsletter here 🔗ow.ly/nzT550Wu2Za
0
0
1
0
60
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 30

The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y

ScleroForum's tweet image. The Scleroderma Research Foundation (#SRF) featured #SclerodermaForum in its July eNewsletter. 🗞️ Access the newsletter today. 🔗ow.ly/lUx450Wu36Y
0
0
1
0
57
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug

ScleroForum's tweet image. 🌟Following last month’s launch at #EULAR, #SclerodermaForum is featured in the July eNewsletter from The Scleroderma Research Foundation (#SRF). Visit the newsletter today 🔗ow.ly/lS6T50Wu2Ug
0
0
1
0
68
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 31

After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG

ScleroForum's tweet image. After the successful launch of #SclerodermaForum at this year’s #EULAR, The Scleroderma Research Foundation (#SRF) has featured us in their July eNewsletter. 📧 Access the newsletter 🔗ow.ly/NliR50Wu3cG
0
0
0
0
64
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 4

Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U

ScleroForum's tweet image. Enhance your understanding of #Scleroderma with our newly uploaded slide decks and literature highlights. 👉Visit the #SclerodermaForum today to access these free resources: ow.ly/tlCj50Wnw0U
0
0
1
0
48
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 8

The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8

ScleroForum's tweet image. The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis, as shown by Fretheim et al. 👀See the full insights from the #SclerodermaForum: ow.ly/hm7A50WnvS8
0
0
0
0
40
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 5

In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm

ScleroForum's tweet image. In patients with dcSSc, safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10, are similar to those observed in other approved indications, as shown by Denton et al. 👀See the full insights from the #SclerodermaForum: ow.ly/Fbxf50WnvRm
0
0
0
0
37
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 28

In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum

ScleroForum's tweet image. In systemic sclerosis patients, Fretheim et al. observed that the safety profile of faecal microbiota transplantation with ACHIM was comparable to that of placebo. 👀Learn more here: ow.ly/SOLt50WnvOh #SclerodermaForum
0
0
0
0
25
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 25

Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum

ScleroForum's tweet image. Denton et al. report that weekly SC immunoglobulin and monthly IV immunoglobulin were well-tolerated in patients with systemic sclerosis. No new safety concerns were observed. 👇👇 ow.ly/3IW450WnvNI #SclerodermaForum
0
0
0
0
33
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Aug 1

This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…

ScleroForum's tweet image. This target trial emulation used real-world data from 208 matched patients with early dcSSc. Both treatment strategies—immunosuppression alone or with GCs—led to similar skin score improvements. 👀See full insights from Mongin et al. #SclerodermaForum scleroderma-forum.com/literature-rev…
0
0
0
0
31
ScleroForum's profile picture. Providing medical education to clinicians around the globe to facilitate greater understanding of scleroderma, its treatments, and clinical practice.
Scleroderma Forum
@ScleroForum
Jul 24

Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY

ScleroForum's tweet image. Fretheim et al. report that 48% of systemic sclerosis patients receiving faecal microbiota transplantation with ACHIM experienced adverse events, mostly mild and short-lived gastrointestinal tract symptoms. 👂Learn more on the #SclerodermaForum: ow.ly/UgEY50WnvMY
0
0
1
0
31

Something went wrong.


Something went wrong.


United States Trends